Medical silicone pressure-sensitive adhesive composition

Abstract

The present invention relates to a compound having at least two C groups per molecule, each bonded to a silicon atom. 2 ~C 6 A medical silicone pressure sensitive adhesive composition comprising at least one organopolysiloxane gum A containing alkenyl groups, at least one organopolysiloxane resin B containing one or more OH groups bonded to silicon atoms, at least one organopolysiloxane extender CE having exactly two terminal hydrogen atoms bonded to silicon atoms, optionally at least one organopolysiloxane crosslinker XL having at least three hydrogen atoms bonded to silicon atoms, at least one hydrosilylation catalyst D, at least one solvent E and optionally at least one hydrosilylation inhibitor F, wherein the organopolysiloxanes A, CE and XL have a molar ratio RHAlk of 2 to 5 and a ratio nH XL / nH CE is selected so that is less than 0.10.

Description

[Technical Field]

[0001] The field of this invention is the field of medical pressure-sensitive adhesives (PSAs). Specifically, this invention relates to a medical silicone pressure-sensitive adhesive composition, a method for coating a substrate using a medical silicone pressure-sensitive adhesive composition, and a skin-adhesive article that can be obtained by this method. [Background technology]

[0002] PSA is an abbreviation for "pressure-sensitive adhesive," a term well-known in the field and widely used in various applications, particularly in medical applications. Currently, in the medical market, most skin-contact products, such as tapes, patches, and bandages, are made with acrylic PSA. However, acrylic PSA has several drawbacks, such as poor sweat resistance (water resistance), poor biocompatibility, and a high sensitization rate to human skin, especially infants.

[0003] Furthermore, silicone-based PSAs are widely used in medical applications for use on or in contact with the skin. Silicone-based PSAs can easily adhere to surfaces by contact or under light pressure. This offers significant advantages over acrylic-based PSAs. Silicone-based PSAs exhibit favorable properties for medical applications due to their breathability, water resistance, low irritancy, and biocompatibility. For example, their biocompatibility and permeability make them suitable for the demanding requirements of novel medical applications, allowing for the diffusion of oxygen, carbon dioxide, and water vapor, which is preferable for medical applications where breathability is required.

[0004] WO2017 / 158249Al and WO2017 / 051083 disclose skin-adhesive silicone gels. Due to their inherent properties, silicone gels do not adhere to moist skin and are therefore beneficial for wound care applications as they can avoid secondary damage to wounds during bandage use. However, in non-traumatic medical materials applied to the skin, humid environments or sweating often cause the gel to lose its tackiness and subsequently peel off.

[0005] US2007 / 0202245Al discloses a method for improving the adhesion of silicone gels to medical substrates by including a hydroxy-substituted siloxane resin in the gel formulation. Nevertheless, the improved formulation disclosed in this document is still a silicone gel.

[0006] WO2020 / 099999Al describes a medical silicone pressure-sensitive adhesive. The silicone composition is cured by a polycondensation reaction: the condensation product is formed by the reaction between a polyorganosiloxane containing terminal hydroxyl groups and a silicate resin, to which a non-reactive polyorganosiloxane is then added. In the subsequent tape manufacturing process, an electron beam is used to promote crosslinking of the non-reactive polyorganosiloxane, thereby forming a layer of pressure-sensitive adhesive on the substrate. The manufacturing process of this PSA is complex, and controlling the condensation reaction conditions has a significant impact on the quality of the product.

[0007] Therefore, there is a constant need to obtain silicone-based pressure-sensitive adhesive compositions that possess excellent overall properties suitable for medical applications. [Overview of the Initiative]

[0008] This invention solves the problems of the prior art.

[0009] The present invention relates to a medical silicone pressure-sensitive adhesive composition, wherein the medical silicone pressure-sensitive adhesive composition is An organopolysiloxane A comprising at least one organopolysiloxane A per molecule, each containing at least two C2-C6 alkenyl groups bonded to a silicon atom, and an organopolysiloxane A that is an organopolysiloxane gum, A minimum of one organopolysiloxane resin B containing one or more OH groups bonded to a silicon atom, At least one organopolysiloxane extender CE having exactly two terminal hydrogen atoms bonded to a silicon atom, Optionally, at least one organopolysiloxane crosslinking agent XL having at least three hydrogen atoms bonded to a silicon atom, At least one hydrosilylation catalyst D, At least one solvent E, Optionally, at least one hydrosilylation inhibitor F and Includes, Organopolysiloxanes A, CE, and XL have a molar ratio RHAlk = tH / tAlk of 2-5, and a ratio of nH XL / nH CE It is selected such that is less than 0.10, where, tH = the number of moles of hydrogen atoms directly bonded to the silicon atoms in organopolysiloxanes CE and XL. tAlk = the number of moles of alkenyls directly bonded to the silicon atom of organopolysiloxane A. nH XL = This is the number of moles of hydrogen atoms directly bonded to the silicon atoms of organopolysiloxane XL. nH CE This relates to a medical silicone pressure-sensitive adhesive composition, where = the number of moles of hydrogen atoms directly bonded to the silicon atom of organopolysiloxane CE.

[0010] The medical silicone pressure-sensitive adhesive composition according to the present invention is a precursor of silicone pressure-sensitive adhesive G and is crosslinkable by hydrosilylation.

[0011] The present invention further relates to a method for manufacturing a skin-adhesive article, comprising the steps of: continuously or discontinuously coating at least one of two surfaces of a substrate with the medical silicone pressure-sensitive adhesive composition defined above; and crosslinking the aforementioned medical silicone pressure-sensitive adhesive composition to form a silicone pressure-sensitive adhesive G.

[0012] Another object of the present invention is a substrate wherein at least one of the two surfaces of the substrate is a silicone pressure-sensitive adhesive G obtained by crosslinking the medical silicone pressure-sensitive adhesive composition defined above. Continuously or discontinuously This is a skin-adhesive article that includes a coated substrate.

[0013] We have found that medical-grade silicone pressure-sensitive adhesives offering excellent properties suitable for medical applications can be obtained from the silicone pressure-sensitive adhesive composition defined above, which contains either no or very small amounts of organopolysiloxane crosslinking agent XL when the molar ratio RHAlk is 2 to 5.

[0014] Suitable properties for medical-grade silicone pressure-sensitive adhesives include excellent overall characteristics such as ease of tearing, no visible residue on the skin, good adhesion to the substrate, good peel-off adhesion, good tackiness, appropriate peel strength, and acceptable repositioning properties. [Modes for carrying out the invention]

[0015] All viscosities considered herein correspond to the magnitude of the “Newtonian” dynamic viscosity at 25°C, i.e., the dynamic viscosity measured using a Brookfield viscometer in a method known in itself, at a shear rate gradient low enough that the measured viscosity is not affected by the velocity gradient.

[0016] The consistency or penetrability of the gum is typically determined at 25 °C using a penetrometer of the PNR12 type or equivalent model, with a cylindrical head that can be applied to the sample under standardized conditions. The penetrability of the gum is the depth to which a calibrated cylinder penetrates the sample in one minute and is expressed in tenths of a millimeter. For example, the following method is given: A sample of the gum is introduced into an aluminum container with a diameter of 40 mm and a height of 60 mm. The cylindrical head, made of bronze or brass, has a diameter of 6.35 mm and a height of 4.76 mm and is supported by a metal rod with a length of 51 mm and a diameter of 3 mm that fits the penetrometer. This rod has an overload of 100 g applied to it. The total weight of the assembly is 151.8 g, including a 4.3 g cylindrical part and its support rod. The container containing the gum sample is placed in a thermostatically controlled bath at 25 ± 0.5 °C for at least 30 minutes. The measurement is carried out according to the manufacturer's instructions. The value of the depth (V) in tenths of a millimeter and the value of the time (t) in seconds taken to reach this depth are shown on the device. The penetrability is equal to 60V / t and is expressed in tenths of a millimeter per minute.

[0017] In this specification, to describe the polyorganosiloxanes, the nomenclature known in the field of silicones is used, and to describe the siloxy units, the following letters: M, D, T, and Q are used. The letter M represents a monofunctional unit of the formula (R 1 )3SiO 1 / 2 , where the silicon atom is bonded to only one oxygen atom in the polymer containing this unit. The letter D means a difunctional unit (R 1 )2SiO 2 / 2 , where the silicon atom is bonded to two oxygen atoms. The letter T represents a trifunctional unit of the formula (R 1 )SiO 3 / 2 , where the silicon atom is bonded to three oxygen atoms. The letter Q represents a tetrafunctional unit of the formula SiO 4 / 2 , where the silicon atom is bonded to four oxygen atoms. The symbol R 1 represents a group. The M, D, and T units can be functionalized. Next, the M, D, and T units are referred to while specifying certain groups.

[0018] Component A may be a silicone polymer substituted with at least two C2-C6 alkyl groups used as the backbone in the composition.

[0019] Preferably, at least one organopolysiloxane A is (i) At least two siloxyl units of formula (A1): (Y) a (Z) b SiO (4+(a+b))) / 2 (A1) Here, • Y represents a monovalent group containing 2 to 6 carbon atoms and having at least 2 alkenyl groups; ·Z represents a monovalent group containing 1 to 20 carbon atoms and not containing an alkenyl group. a and b represent integers, where a is 1, 2, or 3, b is 0, 1, or 2, and (a+b) is 1, 2, or 3. It can include, and, (ii) Optionally, other siloxyl units of formula (A2): (Z) c SiO (4-c) / 2 (A2) Here, ·Z has the same meaning as above, • c represents an integer of 1, 2, or 3. It can include...

[0020] According to the present invention, in the definition of organopolysiloxane in formula (A1), the symbol a can preferably be equal to 1 or 2, and more preferably to 1. Furthermore, in formulas (A1) and (A2), the symbol Z can preferably be an alkyl group containing 1 to 8 carbon atoms, which may be substituted with at least one halogen atom, and C6 to C 10It can represent a monovalent group selected from the group formed by aryl groups. Z can preferably represent a monovalent group selected from the group formed by methyl, ethyl, propyl, 3,3,3-trifluoropropyl, xylyl, tolyl, and phenyl. In addition, in formula (A1), the symbol Y can preferably represent a group selected from the group consisting of vinyl, propenyl, 3-butenyl, and 5-hexenyl. Preferably, the symbol Y is vinyl and the symbol Z is methyl.

[0021] Organopolysiloxane gum A has a linear structure. It is essentially, ·Formula (Y)2SiO 2 / 2 , (Y)(Z)SiO 2 / 2 and (Z)2SiO 2 / 2 The siloxyl unit "D" selected from the units, and • Formula (Y)3SiO 1 / 2 , (Y)2(Z)SiO 1 / 2 , (Y)(Z)2SiO 1 / 2 and (Z)3SiO 2 / 2 Siloxyl unit "M" selected from the units. It can consist of, Here, the symbols Y and Z in the formula are as defined above.

[0022] Preferably, the linear organopolysiloxane A has a degree of polymerization in the range of 2000 to 10000, more preferably 2000 to 8000, and more preferably 2000 to 5000.

[0023] Examples of the unit "D" include dimethylsiloxy, methylphenylsiloxy, methylvinylsiloxy, methylbutenylsiloxy, methylhexenylsiloxy, methyldecenylsiloxy, and methyldecadienylsiloxy groups.

[0024] Examples of the unit "M" include the trimethylsiloxy, dimethylphenylsiloxy, dimethylvinylsiloxy, and dimethylhexenylsiloxy groups.

[0025] Organopolysiloxane A can be a polymer having a weight-average molecular weight Mw of preferably 260,000 g / mol to 1,000,000 g / mol, preferably 400,000 g / mol to 1,000,000 g / mol, and more preferably 400,000 g / mol to 900,000 g / mol.

[0026] As an example of a useful organopolysiloxane A, • Polydimethylsiloxane containing dimethylvinylsilyl terminal groups, • Poly(methylphenylsiloxane-co-dimethylsiloxane) containing dimethylvinylsilyl terminal groups, • Poly(vinylmethylsiloxane-co-dimethylsiloxane) containing dimethylvinylsilyl terminal groups, • Poly(dimethylsiloxane-co-vinylmethylsiloxane) containing a trimethylsilyl terminal group One could list these:

[0027] It is particularly advantageous that organopolysiloxane A is a polydimethylsiloxane containing a dimethylvinylsilyl terminal group and having a weight-average molecular weight Mw of 260,000 g / mol to 1,000,000 g / mol, preferably 400,000 g / mol to 900,000 g / mol. Particularly advantageous organopolysiloxane A is given by formula M Vi D a M Vi It is, and here, ·M Vi =Formula:(vinyl)(CH3)2SiO 1 / 2 It is a siloxyl unit, ·D=formula:(CH3)2SiO 2 / 2 It is a siloxyl unit, • a is a number between 2000 and 6000, preferably between 3000 and 5500.

[0028] Organopolysiloxane A can be used in an amount of 15% to 45% by weight, preferably 20% to 40% by weight, relative to the total amount of components A + B + XL + CE. According to one embodiment, organopolysiloxane A has an alkenyl content of 0.001% to 0.5% by weight, preferably 0.005% to 0.025% by weight, and more preferably 0.008% to 0.018% by weight, relative to the total amount of organopolysiloxane A.

[0029] Preferably, organopolysiloxane A can be selected from polydimethylsiloxane with dimethylvinyl as a terminal group, polydimethylmethylvinylsiloxane with dimethylvinyl as a terminal group, and polydimethylmethylvinylsiloxane with trimethyl as a terminal group, and more preferably from polydimethylsiloxane with dimethylvinyl as a terminal group.

[0030] According to one embodiment, organopolysiloxane A is an organopolysiloxane gum having a consistency of 200 mm / 10 to 2000 mm / 10 at 25°C, preferably 300 mm / 10 to 1800 mm / 10, and more preferably 500 mm / 10 to 1500 mm / 10.

[0031] According to one embodiment, organopolysiloxane A is an organopolysiloxane gum having a weight-average molecular weight Mw of 260,000 g / mol to 1,000,000 g / mol, preferably 400,000 g / mol to 1,000,000 g / mol, and more preferably 400,000 g / mol to 900,000 g / mol. The weight-average molecular weight Mw is determined by gel permeation chromatography using polystyrene as the standard.

[0032] According to one embodiment, organopolysiloxane A is an organopolysiloxane gum exhibiting a viscosity higher than 600,000 mPa·s at 25°C, preferably higher than 1,000,000 mPa·s at 25°C.

[0033] According to one embodiment, the medical silicone pressure-sensitive adhesive composition according to the present invention further comprises at least one organopolysiloxane A'' which is an oil having a dynamic viscosity of 10 mPa·s to 500,000 mPa·s at 25°C, preferably 100 mPa·s to 100,000 mPa·s at 25°C, and more preferably 10,000 mPa·s to 100,000 mPa·s at 25°C. The organopolysiloxane A'' may be linear or branched and may have an alkenyl content of 0.05% to 0.5% by weight relative to the total amount of component A''.

[0034] Organopolysiloxane B, which contains a hydroxyl group bonded to a Si atom, can be selected from ordinary organopolysiloxane resins, of which formula (R 2 )3SiCl, (R 2 )2Si(Cl)2, R 2 Examples include organosilicon resins prepared by co-hydrolysis and co-condensation of chlorosilanes selected from the group consisting of Si(Cl)3 and Si(Cl)4. These resins are well-known branched organopolysiloxane oligomers or polymers that are commercially available. In their structure, they are based on the formula (R 2 )3SiO 1 / 2 (M units), (R 2 )2SiO 2 / 2 (D units), R 2 SiO 3 / 2 (in units of T) and SiO 4 / 2 This represents at least two siloxyl units selected from (Q units), where at least one of these units is a T or Q unit. 2 The base is a resin with approximately 0.8 to 1.8 R atoms per silicon atom. 2 The groups are distributed in such a way that they are present. Furthermore, these resins are not completely condensed and contain OH groups. 2 The groups are identical or different and are selected from linear or branched C1-C6 alkyl groups, C2-C4 alkenyl groups, phenyl groups, or 3,3,3-trifluoropropyl groups. For example, alkyl R 2Examples of groups include methyl, ethyl, isopropyl, tert-butyl, and n-hexyl groups, and examples of alkenyl groups include vinyl or allyl groups. Preferably, R 2 The group is either a methyl or hydroxyl group.

[0035] According to a particular embodiment, organopolysiloxane resin B containing a hydroxyl group is a) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 , and Q (OH) =(OH)SiO 3 / 2 M and Q (OH) Contains siloxy units, Optionally, the siloxy unit Q = SiO 4 / 2 MQ is a copolymer in which (OH) Type of hydroxylated silicone resin, b) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 , ·D Vi =(Vi)(R 3 )SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M, D Vi and Q (OH) Contains siloxy units, Optionally, the siloxy unit Q = SiO 4 / 2 MD is a copolymer in which Vi Q (OH) Type of hydroxylated silicone resin, c) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 , ·M Vi =(Vi)(R 3 )(R 4)SiO 2 / 2 and ·Q (OH) =(OH)SiO 3 / 2 of M, M Vi and Q (OH) containing siloxy units, optionally, the siloxy unit Q=SiO 4 / 2 is present, a copolymer of MM Vi Q (OH) type hydroxylated silicone resin, d) The following formula: ·M=R 3 R 4 R 5 SiO 1 / 2 , ·D=R 3 R 4 SiO 2 / 2 , ·T (OH) =(OH)R 3 SiO 2 / 2 , ·T=R 3 SiO 3 / 2 of M, D, T (OH) and a copolymer containing T siloxy units, MDT (OH) T type hydroxylated silicone resin, and e) The following formula: ·D=R 3 R 4 SiO 2 / 2 , ·T (OH) =(OH)R 3 SiO 2 / 2 , ·T=R 3 SiO 3 / 2 of D, T (OH) and a copolymer containing T siloxy units, DT (OH) T type hydroxylated silicone resin selected from the group consisting of, wherein, in the formula, the symbol Vi=vinyl group, and the symbols R 3 , R 4 and R 5 are, independently of each other, • A linear or branched alkyl group having 1 to 8 carbon atoms, optionally substituted with one or more halogen atoms, preferably selected from the group consisting of methyl, ethyl, isopropyl, tert-butyl and n-hexyl groups, and • An aryl or alkylaryl group having 6 to 14 carbon atoms, preferably selected from the group consisting of phenyl, xylyl, and tolyl groups. Selected from.

[0036] In a preferred embodiment, an example of organopolysiloxane resin B may be selected from at least one of MQ resin, MDQ resin, DT resin, and MDT resin, where the OH groups can be supported by Q and / or T units.

[0037] According to another preferred embodiment, organopolysiloxane resin B is MQ (OH) MQQ (OH) Or MM Vi Q (OH) This is a type of hydroxylated silicone resin containing 0.1% to 4% by weight, preferably 0.3% to 2.0% by weight, and more preferably 0.5% to 1.5% by weight of hydroxyl groups relative to the dry weight of organopolysiloxane resin B. Preferably, the ratio of M units to Q units is 0.5 to 1.2, preferably 0.6 to 0.9. Component B can have a weight-average molecular weight Mw of 3000 g / mol to 12000 g / mol, preferably 4000 g / mol to 11000 g / mol.

[0038] In the composition of this invention, organopolysiloxane resin B can be used as a tackifier.

[0039] Organopolysiloxane resin B can be used in an amount of 25% to 80% by weight, preferably 40% to 60% by weight, relative to the total amount of components A + B + XL + CE.

[0040] Preferably, the weight ratio of component B to component A can be 0.8 to 2.5, more preferably 1.0 to 2.0.

[0041] Component CE, also known as a "chain extender" or simply "extender," is an organopolysiloxane having exactly two terminal hydrogen atoms bonded to Si.

[0042] For example, the organopolysiloxane extender CE according to the present invention is Two siloxyl terminal units of formula (CE-1), which may be the same or different: (H)(R 6 )2SiO 1 / 2 (CE-1) Here, Symbol R 6 This is a C1-C8 alkyl group or a C6-C 10 It corresponds to an aryl group, and the symbol H represents a hydrogen atom. • At least two siloxyl units of formula (CE-2): (R 7 )2SiO 2 / 2 (CE-2) Here, the base R 7 This is a C1-C8 alkyl group or a C6-C 10 Corresponding to the aryl group, It can include, However, the organopolysiloxane CE contains two hydrogen atoms per polymer, each hydrogen atom bonded to a different silicon atom, and preferably, the organopolysiloxane CE contains two siloxy units of formula (CE-1) and at least one siloxy unit of formula (CE-2) per polymer.

[0043] Examples of organopolysiloxane CEs include polydimethylsiloxanes containing dimethylhydrogensilyl terminal groups and having a dynamic viscosity at 25°C of 1 mPa·s to 1000 mPa·s, preferably 5 mPa·s to 500 mPa·s, and more preferably 5 mPa·s to 300 mPa·s. Particularly advantageous organopolysiloxane CEs are those of formula M H D X M H It is, and here, ·M H=Formula:(H)(CH3)2SiO 1 / 2 It is a siloxyl unit, ·D=formula:(CH3)2SiO 2 / 2 It is a siloxyl unit, x is an integer between 1 and 200, preferably between 1 and 150, and more preferably between 3 and 120.

[0044] Organopolysiloxane CE is described as a "chain extender" because, when the SiH-reactive functional group is located at the chain end, it is presumed to have the effect of increasing the mesh size of the network structure during crosslinking.

[0045] The component CE may have a dynamic viscosity at 25°C of 1 mPa·s to 1000 mPa·s, preferably 5 mPa·s to 500 mPa·s, and more preferably 5 mPa·s to 300 mPa·s.

[0046] The Si-H content of component CE can be 0.2% to 10% by weight, preferably 0.3% to 8.0% by weight, and more preferably 0.4% to 6.0% by weight, relative to the total weight of component CE.

[0047] Preferably, the organopolysiloxane extender CE can be a polydimethylsiloxane having dimethylhydrogen as a terminal group.

[0048] The organopolysiloxane extender CE can be used in an amount of 5% to 20% by weight relative to the total amount of components A + B + XL + CE.

[0049] Unlike the chain extender CE, component XL, also referred to as the "crosslinking agent," is an organopolysiloxane having at least three hydrogen atoms bonded to Si. The organopolysiloxane crosslinking agent XL is an optional component of the composition according to the present invention. If an organohydrogensiloxane crosslinking agent XL is present, it may be as disclosed below.

[0050] For example, the organohydrogensiloxane crosslinking agent XL according to the present invention is • At least three siloxyl units of formula (XL-1): (H)(L) e SiO (3-e) / 2 (XL-1) Here, the symbol H represents a hydrogen atom, and the symbol L represents an alkyl group having 1 to 8 carbon atoms or C6-C6. 10 The letter aryl is represented, and the symbol e is equal to 0, 1 or 2, and • Optionally, other siloxy units in formula (XL-2): (L) g SiO (4-g) / 2 (XL-2) Here, the symbol L represents an alkyl group having 1 to 8 carbon atoms or C6-C6 10 Representing an aryl, the symbol g is equal to 0, 1, 2, or 3. It can include, However, the organopolysiloxane XL is subject to the condition that it contains 0.5% to 15.0% by weight of Si-H functional groups per polymer, preferably 1.0% to 12.5% ​​by weight of Si-H functional groups per polymer, and more preferably 1.5% to 10.0% by weight of Si-H functional groups per polymer.

[0051] The organopolysiloxane XL according to the present invention, which has a crosslinkable functional group and is useful, is given by formula M H D x D H w M H M H D x D H y M and MD x D H z We can list the items of M, and here in the formula, ·M H =Formula:(H)(CH3)2SiO 1 / 2 It is a siloxyl unit, ·D H =Formula:(H)(CH3)SiO 2 / 2 It is a siloxyl unit, ·D=formula:(CH3)2SiO 2 / 2 It is a siloxyl unit, ·M=Formula (CH3)3SiO 1 / 2 It is a siloxyl unit, X is a number between 0 and 500, preferably between 2 and 250, and more preferably between 5 and 80. w is a number from 1 to 500, preferably 1 to 250 or 1 to 100, and more preferably 1 to 70. y is a number between 2 and 500, preferably 3 to 250 or 2 to 100, and more preferably 2 to 70. z is a number between 3 and 500, preferably 3 to 250 or 3 to 100, and more preferably 3 to 70. The polymer contains 0.5% to 15.0% by weight of Si-H functional groups per polymer, preferably 1.0% to 12.5% ​​by weight of Si-H functional groups per polymer, and more preferably 1.5% to 10.0% by weight of Si-H functional groups per polymer.

[0052] Component XL can have a dynamic viscosity of 40 mPa·s to 1000 mPa·s at 25°C, preferably 50 mPa·s to 750 mPa·s at 25°C, and more preferably 60 mPa·s to 500 mPa·s at 25°C. If the viscosity of component XL is less than 40 mPa·s at 25°C, the hardened PSA will aggregate too strongly and will not peel off easily. Furthermore, strong aggregation will result in weak adhesion to the substrate, leaving fragments as residue on the skin when the hardened PSA layer is peeled off.

[0053] The Si-H content of component XL can be 0.5% to 15% by weight, preferably 1.0% to 12.5% ​​by weight, and more preferably 1.5% to 10.0% by weight, relative to the total weight of component XL.

[0054] Preferably, the organopolysiloxane crosslinking agent XL can be a polymethylhydrogensiloxane with trimethylsiloxy as a terminal group, or a polymethylhydrogensiloxane with dimethylhydrogen as a terminal group.

[0055] The content of organopolysiloxanes A, CE, and XL in the composition according to the present invention is as follows: ·Ratio RHAlk=tH / tAlk ·ratio nH XL / nH CE Selected by, Here, ·tH = the number of moles of hydrogen atoms directly bonded to the silicon atoms of organopolysiloxanes CE and XL. tAlk = the number of moles of alkenyls directly bonded to the silicon atom of organopolysiloxane A. ·nh XL = This is the number of moles of hydrogen atoms directly bonded to the silicon atoms of organopolysiloxane XL. ·nh CE = This is the number of moles of hydrogen atoms directly bonded to the silicon atom in organopolysiloxane CE.

[0056] According to the present invention, the molar ratio RHAlk is 2 to 5, preferably 2.5 to 4. According to the present invention, the ratio nH XL / nH CE The value is less than 0.10, preferably 0 to 0.08, and more preferably 0 to 0.05. According to a preferred embodiment, the composition according to the present invention does not contain or substantially contains the organohydrogensiloxane crosslinking agent XL.

[0057] As useful hydrosilylation catalysts D according to the present invention, compounds of metals belonging to the platinum group, which are well known to those skilled in the art, can be cited. Platinum group metals are known as platinumoids, which are the names given to the group formed by combining platinum with ruthenium, rhodium, palladium, osmium, and iridium. Compounds of platinum and rhodium are preferred. In particular, complexes of platinum and organic products described in patents US3,159,601, US3,159,602 and US3,220,972 and European patents EP0057459, EP0188978 and EP0190530, as well as complexes of platinum and vinyl organosiloxane described in patent US3,419,593 can be used. Generally, platinum is the preferred catalyst. Examples include, in particular, black platinum, chloroplatinic acid, chloroplatinic acid modified with alcohol, and complexes of chloroplatinic acid with olefins, aldehydes, vinylsiloxanes, or acetylene alcohols. A platinum catalyst containing a Karstedt solution or complex, hexahydrate chlorplatinic acid, or a carbene ligand, as described in Japanese Patent US3,775,452, is preferred.

[0058] Preferably, component D is a solution of a platinum complex in a polydimethylsiloxane with vinyl as the terminal group.

[0059] According to one embodiment of the present invention, solvent E is C6~C 16 The following are selected from the group consisting of aliphatic hydrocarbons, polydimethylsiloxanes containing trimethylsilyl terminal groups and having a viscosity of 0.65 mPa·s to 5 mPa·s at 25°C: polydimethylsiloxanes, cyclic polydimethylsiloxanes, (3-octyl)heptamethyltrisiloxanes, toluene, xylene, C1-C8 alkyl esters, C2-C4 carboxylic acids and mixtures thereof.

[0060] In particular, solvent E is at least one solvent. Solvent E is at least one solvent approved for medical use. For example, it is selected from toluene, xylene, heptane, ethyl acetate, and more preferably ethyl acetate for medical use.

[0061] The amount of solvent is 20% to 70% by weight, preferably 30% to 60% by weight, relative to the total weight of the composition.

[0062] Hydrosilylation inhibitor F can be used in this composition.

[0063] Examples of useful hydrosilylation inhibitors according to the present invention include α-acetylene alcohols, α,α'-acetylenediesters, enyne conjugated compounds, α-acetylene ketones, acrylonitriles, maleates, fumarates, and mixtures thereof. These compounds can act as hydrosilylation inhibitors and are well known to those skilled in the art. They can be used individually or in mixtures.

[0064] α-acetylene alcohol type inhibitors are selected from compounds of the following formula (F1): [ka] Here, ·R 8 The groups are alkyl groups, cycloalkyl groups, (cycloalkyl)alkyl groups, and C6-C6 groups. 10 Aryl group or C7~C 18 Represents an arylalkyl group, ·R 9 The group consists of a hydrogen atom, alkyl group, cycloalkyl group, (cycloalkyl)alkyl group, and C6-C6 10 Aryl group or C7~C 18 Represents an arylalkyl group, · Or, R 8 and R 9 Together with the carbon atoms to which they are bonded, they form a 5-membered, 6-membered, 7-membered, or 8-membered aliphatic ring which may be substituted one or more times.

[0065] According to formula (F1), The term "alkyl" is understood to mean a saturated hydrocarbon chain containing 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. Alkyl groups can be selected from the group consisting of methyl, ethyl, isopropyl, n-propyl, tert-butyl, isobutyl, n-butyl, n-pentyl, isoamyl, and 1,1-dimethylpropyl. The term "cycloalkyl" is understood, according to the present invention, to mean a saturated monocyclic or polycyclic, preferably monocyclic or bicyclic hydrocarbon group containing 3 to 20 carbon atoms, preferably 5 to 8 carbon atoms. When a cycloalkyl group is polycyclic, multiple ring nuclei can be bonded to each other via covalent bonds and / or via spiran atoms, and / or condensed to each other. Cycloalkyl groups can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantane, and norbornane. According to the present invention, the term "(cycloalkyl)alkyl" is understood to mean a cycloalkyl group as defined above that is bonded to an alkyl group as defined above. The term "aryl" is understood, according to the present invention, to mean an aromatic hydrocarbon group containing 6 to 10 carbon atoms, which is monocyclic or polycyclic. The aryl group can be selected from the group consisting of phenyl, naphthyl, and anthracenyl. According to the present invention, the term "arylalkyl" is understood to mean a group in which the aryl group defined above is bonded to an alkyl group also defined above.

[0066] According to a preferred embodiment, in formula (F1), R 8 and R 9 These, together with the carbon atoms to which they are bonded, form an unsaturated 5-membered, 6-membered, 7-membered, or 8-membered aliphatic ring. According to another preferred embodiment, R 8 and R 9 These are either identical or different, and are independent of each other, monovalent C1~ 12 Preferably, it represents an alkyl group of C1 to C6.

[0067] Useful α-acetylene alcohol inhibitors according to the present invention can be selected from the group consisting of the following compounds: 1-ethynyl-1-cyclopentanol; 1-ethynyl-1-cyclohexanol (also known as ECH); 1-ethynyl-1-cycloheptanol; 1-ethynyl-1-cyclooctanol; 3-methyl-1-butin-3-ol (also known as MBT); 3-methyl-1-pentin-3-ol; 3-methyl-1-hexyn-3-ol; 3-methyl-1-heptin-3-ol; 3-methyl-1-octin-3-ol; 3-methyl-1-nonin-3-ol; 3-methyl-1-decine-3-ol; 3-methyl-1-dodecine-3-ol; 3-methyl-1-pentadecin-3-ol; 3-ethyl-1-pentadecine-3-ol N-3-ol; 3-ethyl-1-hexyn-3-ol; 3-ethyl-1-heptin-3-ol; 3,5-dimethyl-1-hexyn-3-ol; 3-isobutyl-5-methyl-1-hexyn-3-ol; 3,4,4-trimethyl-1-pentin-3-ol, 3-ethyl-5-methyl-1-heptin-3-ol; 3,6-diethyl-1-nonin-3-ol; 3,7,11-trimethyl-1-dodecine-3-ol (also known as TMDDO); 1,1,-diphenyl-2-propyne-1-ol; 3-butyn-2-ol; 1-pentin-3-ol; 1-hexyn-3-ol; 1-heptin-3-ol; 5-methyl-1-hexyn-3-ol; 4-ethyl-1-octin-3-ol and 9-ethynyl-9-fluorenol.

[0068] α,α'-acetylenediester type inhibitors are selected from compounds of the following formula (F2): [ka] Here, R 10 and R 11 The groups are either the same or different, and independently of each other, they are alkyl groups, cycloalkyl groups, (cycloalkyl)alkyl groups, and C6-C 10 Aryl group, C7~C 18Represents an arylalkyl group or a silyl group.

[0069] The term "silyl" is understood in this invention to mean a group of formula -SiR3, where each R symbol independently represents an alkyl group containing 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. The silyl group can be, for example, a trimethylsilyl group.

[0070] According to a particular embodiment, in formula (F2), R 10 and R 11 The bases are either the same or different, and are independent of each other, C1~C 12 Preferably, it represents a C1-C6 alkyl group or a trimethylsilyl group. Useful α,α'-acetylenediester inhibitors according to the present invention can be selected from the group consisting of the following compounds: dimethylacetylenedicarboxylate (DMAD), diethylacetylenedicarboxylate, di(tert-butyl)acetylenedicarboxylate, and bis(trimethylsilyl)acetylenedicarboxylate.

[0071] Enyne-conjugated compound type inhibitors can be selected from compounds of the following formula (F3): [ka] Here, ·R 12 , R 13 and R 14 The groups are, independently of each other, a hydrogen atom, an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, and C6-C6. 10 Aryl group, or C7~C 18 Represents an arylalkyl group, · Or, R 12 , R 13 and R 14 At least two of the groups, together with the one or more carbon atoms to which they are bonded, constitute a five-membered, six-membered, seven-membered, or eight-membered aliphatic ring which may be substituted one or more times.

[0072] According to a particular embodiment, R 12 , R 13 and R 14 The groups are independent of each other: hydrogen atoms, C1-C 12 Preferably C1-C6 alkyl groups or C6-C 10 Represents an aryl group. The useful enyne conjugated inhibitor according to the present invention can be selected from the group consisting of the following compounds: 3-methyl-3-penten-1-yine; 3-methyl-3-hexen-1-yine; 2,5-dimethyl-3-hexen-1-yine; 3-ethyl-3-buten-1-yine; and 3-phenyl-3-buten-1-yine. According to another specific embodiment, R 12 , R 13 and R 14 Two groups selected from the group, together with the one or more carbon atoms to which they are bonded, form an unsaturated 5-membered, 6-membered, 7-membered, or 8-membered aliphatic ring, and the remaining third group is a hydrogen atom or C1-C 12 Preferably, it represents a C1-C6 alkyl group. A useful enyne-conjugated inhibitor according to the present invention can be 1-ethynyl-1-cyclohexene.

[0073] α-acetylene ketone type inhibitors can be selected from compounds of the following formula (F4): [ka] Here, R 15 These include alkyl groups, cycloalkyl groups, (cycloalkyl)alkyl groups, and C6-C6 10 Aryl group or C7~C 18 The term "arylalkyl group" represents an alkyl group, cycloalkyl group, (cycloalkyl)alkyl group, aryl group, or arylalkyl group, which may be optionally substituted one or more times with a chlorine atom, a bromine atom, or an iodine atom.

[0074] According to a preferred embodiment, R 15 This is a monovalent C1~ which may be substituted once or more by a chlorine atom or a bromine atom. 12 Preferably a C1-C6 alkyl group, or a cycloalkyl group, or a C6-C10 This represents an aryl group. The useful α-acetylene ketone inhibitors according to the present invention can be selected from the group consisting of the following compounds: 1-octin-3-one, 8-chloro-1-octin-3-one; 8-bromo-1-octin-3-one; 4,4-dimethyl-1-octin-3-one; 7-chloro-1-heptin-3-one; 1-hexin-3-one; 1-pentin-3-one; 4-methyl-1-pentin-3-one; 4,4-dimethyl-1-pentin-3-one; 1-cyclohexyl-1-propyne-3-one; benzoacetylene and (o-chlorobenzoyl)acetylene.

[0075] Acrylonitrile-type inhibitors can be selected from compounds of the following formula (F5): [ka] Here, R 16 and R 17 These are, independently of each other, a hydrogen atom, a chlorine atom, a bromine atom or an iodine atom, an alkyl group, a cycloalkyl group, a (cycloalkyl)alkyl group, and C6-C6. 10 Aryl group or C7~C 18 The term "arylalkyl group" represents an alkyl group, cycloalkyl group, (cycloalkyl)alkyl group, aryl group, or arylalkyl group, which may be optionally substituted one or more times with a chlorine atom, a bromine atom, or an iodine atom.

[0076] The useful acrylonitrile inhibitors according to the present invention can be selected from the group consisting of the following compounds: acrylonitrile; methacrylonitrile; 2-chloroacrylonitrile; crotononitrile and cinnamonitrile.

[0077] Maleate or fumarate-type inhibitors can be selected from the compounds of the following formulas (F6) and (F7): [ka] Here, R 18 and R 19These are either the same or different, and independently of each other, they are alkyl or alkenyl groups, cycloalkyl groups, (cycloalkyl)alkyl groups, C6-C 10 Aryl group, or C7~C 18 This represents an arylalkyl group, and the aforementioned alkyl groups, alkenyl groups, cycloalkyl groups, (cycloalkyl)alkyl groups, aryl groups, and arylalkyl groups can be substituted with alkoxy groups.

[0078] The term "alkenyl" is understood, according to the present invention, to mean a saturated hydrocarbon chain containing 2 to 6 carbon atoms and at least one double unsaturated group. Preferably, the alkenyl group is selected from the group consisting of vinyl and allyl. The term "alkoxy" is understood, according to formulas (F6) and (F7), to mean an alkyl group defined above that is bonded to an oxygen atom. The alkoxy group can be selected from the group consisting of methoxy, ethoxy, propoxy and butoxy.

[0079] According to a particular embodiment, R 18 and R 19 These are either the same or different, and may be independently substituted with C1-C6 alkoxy groups. 12 Preferably, it represents a C1-C6 alkyl group or alkenyl group.

[0080] The useful maleate or fumarate inhibitors according to the present invention can be selected from the group consisting of diethyl fumarate, diethyl maleate, diallyl fumarate, diallyl maleate, and bis(methoxyisopropyl) maleate.

[0081] These inhibitors can be added in amounts of 1 ppm to 50,000 ppm by weight, particularly 10 ppm to 10,000 ppm, preferably 20 ppm to 2,000 ppm, and more preferably 800 ppm to 2,000 ppm, relative to the total weight of the silicone composition.

[0082] The medical silicone pressure-sensitive adhesive composition according to the present invention can be applied to a variety of substrates suitable for medical applications. Depending on the field of application, the substrate can be a support with a wide variety of properties.

[0083] According to a preferred embodiment, the substrate is a woven textile product, a nonwoven textile product, or a knitted textile product, or a plastic film. The term "nonwoven" is understood to mean any structure made of fibrous material, such as fibers, continuous filaments, or cut threads, which is formed into a network by any means other than entanglement of threads, and is bound by any means, regardless of its nature or origin. Nonwoven products have the appearance of a textile product, are porous, are mainly composed of fibers, and are manufactured by processes other than spinning, weaving, knitting, or knotting.

[0084] In another preferred embodiment, the substrate is made of plastic. A wide variety of plastics can be suitable for use as a substrate according to the present invention. Examples include polyvinyl chloride, polypropylene, regenerated cellulose, polyethylene terephthalate (PET), and polyurethane, particularly meltblown polyurethane. The substrate can be a perforated flexible polyurethane film or a continuous flexible polyurethane film. This flexible polyurethane film can be manufactured from meltblown polyurethane. When the substrate is a flexible polyurethane film, its thickness is generally 5 μm to 600 μm, preferably 5 μm to 250 μm, and more preferably 10 μm to 100 μm.

[0085] Alternatively, the base material can be selected from paper, nonwoven fabric, and elastic fabric.

[0086] According to a preferred embodiment, the substrate can be selected from paper, nonwoven fabric, elastic fabric, or plastic film, preferably a plastic film selected from the group consisting of polyvinyl chloride, polypropylene, regenerated cellulose, polyethylene terephthalate (PET), and polyurethane.

[0087] Those skilled in the art can prepare medical silicone pressure-sensitive adhesive compositions according to their end-use. Generally, the medical silicone pressure-sensitive adhesive composition according to the present invention may have a dynamic viscosity at 25°C of 500 mPa·s to 5000 mPa·s, preferably 800 mPa·s to 3000 mPa·s, and more preferably 1000 mPa·s to 2500 mPa·s.

[0088] The medical silicone pressure-sensitive adhesive composition according to the present invention can be applied or coated onto various substrates by any technique well known to those skilled in the art. Techniques for depositing the medical silicone pressure-sensitive adhesive composition according to the present invention include, for example, coating techniques performed by knife, particularly knife-over-roll, floating knife, and knife-over-carpet; padding, i.e., by pressing between two rolls; or by licking roll, rotating machine, reverse roll, or transfer; or by spraying. Another coating technique is the curtain coating technique. Curtain coating is a method of applying a coating liquid to an article or support. Curtain coating is characterized by the formation of a freely falling curtain of coating liquid, which, under the influence of gravity, falls from the lip of a hopper, advancing the curtain to form a coating and contact the article. This technique is widely used in the field of preparing multilayer photosensitive silver supports (see, for example, patents US3,508,947, US3,508,947 and EP537086).

[0089] Next, the medical-grade silicone pressure-sensitive adhesive composition coated on the substrate is crosslinked at a temperature of, for example, 100°C to 160°C, preferably 120°C to 150°C.

[0090] In this way, a substrate coated with the silicone pressure-sensitive adhesive G is obtained by crosslinking the silicone pressure-sensitive adhesive composition according to the present invention.

[0091] Other advantages and features of the present invention will become apparent from reading the following embodiments, which are provided for illustrative purposes and are not intended to limit them. [Examples]

[0092] Probe tack test The tack test is performed by cutting the cured PSA lamination into 2.5 cm (length) x 2.5 cm (width) strips, removing the release liner from the PSA layer, and performing the tack test using a PT1000 probe tack tester manufactured by Cheminustrument Co. Ltd. in accordance with ASTM D2979. The atmospheric conditions are 23°C and 50% RH.

[0093] Peel-off adhesive strength The peel adhesion test is performed by cutting the cured PSA lamination into 2.5 cm (length) x 2.5 cm (width) strips, removing the release liner from the PSA layer, adhering the PSA layer to 15 cm x 5 cm card paper, and laminating them for two cycles using a 2 kg rubber roller. The peel test is then performed according to FINAT FTM1 using a PA1000-180 peel tester manufactured by Cheminstrument Co. Ltd. The atmospheric conditions are 23°C and 50% RH.

[0094] The raw materials used in the examples are shown below. Organopolysiloxane A: Polydimethylsiloxane gum M with vinyl as the terminal group Vi D x M Vi , Mw=560,000g / mol, vinyl content=0.015wt%, consistency=800mm / 10 Organopolysiloxane resin B:M x Q y Q (OH) z Resin, Mw=5,500g / mol, x / (y+z)=0.9, OH=1.0% by weight Extension agent CE: Polydimethylsiloxane oil with hydrogen as the terminal group M H D y M H, viscosity=8.0mPa·s, Si-H content=5.51wt% Catalyst D: Pt content = 0.2% by weight, dissolved in polydimethylsiloxane with vinyl as the terminal group at 350 mPa·s. Solvent E: Ethyl acetate

[0095] Examples 1-5 All ingredients were uniformly mixed in the amounts shown in the table below. Using a blade, the obtained composition is coated onto a PET film (60-90 g / m²). 2 Next, it was placed in a 120°C oven for 30 minutes.

[0096] [Table 1]

[0097] The composition according to the present invention (Example 3) provides an adhesive with very good properties after curing, which was advantageous for use as a medical PSA. Below the claimed molar ratio RHAlk (Examples 1 and 2), the composition Aggregated network It did not show that the requested molar ratio RHAlk was exceeded (Examples 4 and 5). , hard The modified composition lost its peeling properties and appeared to be closer to an elastomer.

Claims

1. A medical silicone pressure-sensitive adhesive composition, wherein the medical silicone pressure-sensitive adhesive composition is Each molecule contains at least two carbon atoms bonded to a silicon atom. 2 ~C 6 An organopolysiloxane A comprising at least one alkenyl group, wherein the organopolysiloxane A is an organopolysiloxane gum, A minimum of one organopolysiloxane resin B containing one or more OH groups bonded to a silicon atom, At least one organopolysiloxane extender CE having exactly two terminal hydrogen atoms bonded to a silicon atom, Optionally, at least one organopolysiloxane crosslinking agent XL having at least three hydrogen atoms bonded to a silicon atom, At least one hydrosilylation catalyst D, At least one solvent E, Optionally, at least one hydrosilylation inhibitor F and Includes, The organopolysiloxane A, the organopolysiloxane extender CE, and the organopolysiloxane crosslinking agent XL have a molar ratio RHAlk = tH / tAlk of 2 to 5, and a ratio nH XL / nH CE It is selected such that it is less than 0.10, where, thH = the number of moles of hydrogen atoms directly bonded to the silicon atoms of the organopolysiloxane extender CE and the organopolysiloxane crosslinking agent XL. tAlk = the number of moles of alkenyls directly bonded to the silicon atoms of the organopolysiloxane A. nH XL = This is the number of moles of hydrogen atoms directly bonded to the silicon atoms of the organopolysiloxane crosslinking agent XL. nH CE = This is the number of moles of hydrogen atoms directly bonded to the silicon atoms of the organopolysiloxane extender CE. The organopolysiloxane A is used in an amount of 15% to 45% by weight relative to the total amount of components A + B + XL + CE. The organopolysiloxane resin B is used in an amount of 25% to 80% by weight relative to the total amount of components A + B + XL + CE. The organopolysiloxane A is a medical silicone pressure-sensitive adhesive composition in which the alkenyl content is 0.001% to 0.5% by weight relative to the total amount of the organopolysiloxane A.

2. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the molar ratio of RHAlk is 2.5 to 4.

3. Said ratio nH XL / nH CE The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the coefficient is exactly less than 0.

10.

4. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the medical silicone pressure-sensitive adhesive composition does not contain or substantially contains organohydrogensiloxane crosslinking agent XL.

5. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the organopolysiloxane A is selected from polydimethylsiloxane with dimethylvinyl as a terminal group, polydimethylmethylvinylsiloxane with dimethylvinyl as a terminal group, and polydimethylmethylvinylsiloxane with trimethyl as a terminal group.

6. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the organopolysiloxane A is an organopolysiloxane gum having a consistency of 200 mm / 10 to 2000 mm / 10 at 25°C.

7. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the organopolysiloxane A is used in an amount of 20% to 40% by weight relative to the total amount of components A + B + XL + CE.

8. The organopolysiloxane resin B containing a hydroxyl group, a) The following formula: M = R 3 R 4 R 5 SiO 1 / 2 and Q (OH) =(OH)SiO 3 / 2 M and Q (OH) Contains siloxy units, Optionally, the siloxy unit Q = SiO 4 / 2 MQ is a copolymer in which (OH) Type of hydroxylated silicone resin, b) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 、 D Vi = (Vi)(R 3 ) SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M, D Vi and Q (OH) Contains siloxy units, Optionally, the siloxy unit Q = SiO 4 / 2 MD is a copolymer in which Vi Q (OH) Type of hydroxylated silicone resin, c) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 、 M Vi = (Vi)(R 3 ) (Caution 4 ) SiO 2 / 2 and Q (OH) =(OH)SiO 3 / 2 M, M Vi and Q (OH) Contains siloxy units, Optionally, the siloxy unit Q = SiO 4 / 2 MM is a copolymer that exists in Vi Q (OH) Type of hydroxylated silicone resin, d) The following formula: M=R 3 R 4 R 5 SiO 1 / 2 、 D=R 3 R 4 SiO 2 / 2 、 T (OH) =(OH)R 3 SiO 2 / 2 、 T=R 3 SiO 3 / 2 M, D, T (OH) and MDT, a copolymer containing T-siloxy units. (OH) T-type hydroxylated silicone resin, and e) The following formula: D=R 3 R 4 SiO 2 / 2 、 T (OH) =(OH)R 3 SiO 2 / 2 、 T=R 3 SiO 3 / 2 D, T (OH) and DT is a copolymer containing T siloxy units. (OH) T-type hydroxylated silicone resin Selected from the group consisting of, In the formula, the symbol Vi represents a vinyl group, and the symbol R represents a vinyl group. 3 , R 4 and R 5 However, they are independent of each other. Linear or branched alkyl groups having 1 to 8 carbon atoms and optionally substituted with one or more halogen atoms, and Aryl or alkylaryl group having 6 to 14 carbon atoms A medical silicone pressure-sensitive adhesive composition according to claim 1, selected from the above.

9. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the organopolysiloxane resin B is used in an amount of 40% to 60% by weight relative to the total amount of components A + B + XL + CE.

10. The organopolysiloxane extender CE is of formula M H D X M H It is represented as, and here, M H =Formula: (H) (CH 3 ) 2 SiO 1 / 2 It is a siloxyl unit, D=Formula: (CH 3 ) 2 SiO 2 / 2 It is a siloxyl unit, The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein x is an integer from 1 to 200.

11. The solvent E is C 6 ~C 16 Polydimethylsiloxane, cyclic polydimethylsiloxane, (3-octyl)heptamethyltrisiloxane, toluene, xylene, C2, containing aliphatic hydrocarbons and trimethylsilyl terminal groups, with a viscosity of 0.65 mPa·s to 5 mPa·s at 25°C. 1 ~C 8 Alkyl ester, C 2 ~C 4 A medical silicone pressure-sensitive adhesive composition according to claim 1, selected from the group consisting of carboxylic acids and mixtures thereof.

12. The medical silicone pressure-sensitive adhesive composition according to claim 1, wherein the amount of solvent E is 20% to 70% by weight relative to the total weight of the medical silicone pressure-sensitive adhesive composition.

13. A method for manufacturing a skin-adhesive article, comprising the steps of: continuously or discontinuously coating at least one of two surfaces of a substrate with a medical silicone pressure-sensitive adhesive composition according to any one of claims 1 to 12; and crosslinking the medical silicone pressure-sensitive adhesive composition to form a silicone pressure-sensitive adhesive G.

14. The method according to claim 13, wherein the substrate is selected from paper, nonwoven fabric, elastic fabric, or plastic film.

15. A skin-adhesive article comprising a substrate, wherein at least one of the two surfaces of the substrate is continuously or discontinuously coated with a silicone pressure-sensitive adhesive G obtained by crosslinking a medical silicone pressure-sensitive adhesive composition according to any one of claims 1 to 12.

Images